Search
Exciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013
Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.
Read moreSelected EMA news
February 2025New medicines recommended for approval
Dyrupeg (pegfilgrastim) – biosimilar
Treatment to shorten the duration of neutropenia and help prevent febrile neutropenia after cytotoxic chemotherapy
Eltrombopag Accord (eltrombopag) – generic
Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C
New information on…
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
EHA-SWG Scientific Meeting on Systemic Risk of Thrombosis or Bleeding
Meeting chairs, Carlo Balduini and Anna Falanga
The meeting was well attended by more than 100 participants coming from over 20 different countries
Delegate: Great meeting.
EHA congratulates the Spanish Society of Hematology on its 60th anniversary
EHA President, John Gribben and member of the SEHH, María Victoria Mateos
On Thursday, June 20 the Spanish Society of Hematology (SEHH) officially celebrated its 60th anniversary with a commemorative event in Madrid.
EHA-AHA hematology tutorial on Biology and Management of Myeloid Malignancies
In 2016, a new hematology center opened in Yerevan, which offers new services, enabling professionals working there to apply theoretical knowledge and advanced approaches in everyday practice.
Read moreJosé Carreras Award handed out at the 17th Congress of EHA
He has made seminal contributions to myeloma cell biology. These included studies of the diagnostic and prognostic roles of immunophenotyping, morphology and molecular genetics together with investigation of disease evolution and the significance of minimal residual disease.
Read moreEMA Issues Call for Expressions of Interest for Drug Safety Studies
The purpose of this call is to enable the EMA to obtain fast and reliable answers to questions on safety or benefit/risk concerns, and ultimately facilitating regulatory decision-making.
Read moreEHA-ECL led statement calls for protection of the Hospital Exemption
The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.
Read moreEHA mapping of adolescent and young adult (AYA) hematology patient care
EHA has launched a major consultation to understand patient care for Adolescents and Young Adults (AYA) with hematological diagnoses across Europe.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- »